Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog. Duker, G., Almgren, O., & Carlsson, L. J Cardiovasc Pharmacol, 20(3):458--465, September, 1992.
  author =       "G. Duker and O. Almgren and L. Carlsson",
  title =        "Electrophysiologic and hemodynamic effects of {H}
                 234/09 (almokalant), quinidine, and (+)-sotalol in the
                 anesthetized dog.",
  journal =      "J Cardiovasc Pharmacol",
  year =         "1992",
  month =        sep,
  volume =       "20",
  number =       "3",
  pages =        "458--465",
  robnote =      "The electrophysiologic and hemodynamic effects of H
                 234/09 (Almokalant), a novel class II antiarrhythmic
                 agent, were studied in the anesthetized dog. H 234/09
                 (1.0 mumol/kg i.v.) significantly prolonged the atrial
                 and ventricular effective refractory periods, the
                 ventricular monophasic action potential duration, and
                 the paced QT interval. At this dose, atrial,
                 ventricular, and atrioventricular conduction was not
                 affected, aortic blood pressure was not changed, and
                 contractile force was transiently increased. The
                 effects on cardiac repolarization and refractoriness
                 induced by H 234/09 were both larger and more long
                 lasting than the effects observed after quinidine (11.8
                 mumol/kg) and (+)-sotalol (9.7 mumol/kg). In
                 conclusion, H 234/09 has electrophysiological
                 properties suggestive of a class III antiarrhythmic.",
  bibdate =      "Fri Jul 19 14:09:47 2002",

Downloads: 0